Caris Life Sciences (NASDAQ:CAI) Shares Cross Below 200-Day Moving Average - Should You Sell?

Caris Life Sciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Caris Life Sciences shares fell below their 200-day moving average, touching $20.95 and last trading at $21.00, below the $21.68 average.
  • Analysts maintain a Moderate Buy consensus, with an average price target of $31.18; ratings include eight Buys, five Holds, and one Sell.
  • Quarterly results beat earnings estimates, with EPS of $0.05 versus $0.03 expected, while revenue rose 27% year over year to $275.36 million.
  • Five stocks we like better than Caris Life Sciences.

Caris Life Sciences, Inc. (NASDAQ:CAI - Get Free Report) crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $21.68 and traded as low as $20.95. Caris Life Sciences shares last traded at $21.00, with a volume of 3,699,328 shares trading hands.

Analysts Set New Price Targets

CAI has been the subject of several recent research reports. TD Cowen raised their price target on shares of Caris Life Sciences from $36.00 to $38.00 and gave the company a "buy" rating in a research report on Thursday, November 5th. JPMorgan Chase & Co. increased their target price on shares of Caris Life Sciences from $25.00 to $35.00 and gave the company an "overweight" rating in a research report on Wednesday, October 14th. Citigroup lifted their target price on Caris Life Sciences from $28.00 to $36.00 and gave the stock a "buy" rating in a research report on Friday, November 6th. Canaccord Genuity Group boosted their target price on Caris Life Sciences from $22.00 to $30.00 and gave the company a "hold" rating in a report on Monday, October 19th. Finally, Evercore reissued an "outperform" rating and issued a $26.00 target price on shares of Caris Life Sciences in a research report on Thursday, August 6th. Eight equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Caris Life Sciences has a consensus rating of "Moderate Buy" and an average price target of $31.18.

Check Out Our Latest Research Report on Caris Life Sciences

Caris Life Sciences Trading Down 8.9%

The company has a debt-to-equity ratio of 0.61, a current ratio of 6.71 and a quick ratio of 5.84. The business's 50-day simple moving average is $29.31 and its 200-day simple moving average is $21.68. The company has a market cap of $6.02 billion, a price-to-earnings ratio of 63.64, a PEG ratio of 7.81 and a beta of 0.71.

Caris Life Sciences (NASDAQ:CAI - Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.02. Caris Life Sciences had a return on equity of 16.00% and a net margin of 9.16%. The company had revenue of $275.36 million during the quarter. During the same period in the previous year, the business posted $0.08 EPS. The business's quarterly revenue was up 27.0% on a year-over-year basis. Research analysts predict that Caris Life Sciences, Inc. will post 0.11 earnings per share for the current fiscal year.

Insider Transactions at Caris Life Sciences

In other news, insider John Russel Denton sold 7,500 shares of Caris Life Sciences stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $31.82, for a total value of $238,650.00. Following the completion of the sale, the insider owned 174,855 shares of the company's stock, valued at $5,563,886.10. The trade was a 4.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, President David Spetzler sold 119,212 shares of Caris Life Sciences stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $24.76, for a total value of $2,951,689.12. Following the completion of the sale, the president owned 1,182,871 shares of the company's stock, valued at $29,287,885.96. This trade represents a 9.16% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 1,004,712 shares of company stock worth $27,205,419 over the last quarter. 50.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Caris Life Sciences

A number of hedge funds have recently made changes to their positions in CAI. PNC Financial Services Group Inc. increased its stake in Caris Life Sciences by 839.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,644 shares of the company's stock worth $29,000 after buying an additional 1,469 shares during the period. Fifth Third Bancorp bought a new stake in Caris Life Sciences in the first quarter valued at $31,000. MCF Advisors LLC acquired a new position in Caris Life Sciences during the 2nd quarter valued at about $36,000. Trifecta Capital Advisors LLC bought a new position in Caris Life Sciences in the 2nd quarter worth approximately $37,000. Finally, GAMMA Investing LLC increased its holdings in shares of Caris Life Sciences by 133.0% during the third quarter. GAMMA Investing LLC now owns 1,263 shares of the company's stock valued at $39,000 after purchasing an additional 721 shares during the period.

Caris Life Sciences Company Profile

(Get Free Report)

Caris Life Sciences is a precision medicine company that develops molecular profiling and artificial intelligence technologies to support cancer diagnosis and treatment decisions. Its services analyze the biological characteristics of a patient's tumor to help physicians identify information that may guide care. The company's offerings include tumor profiling based on DNA and RNA analysis, as well as blood-based testing. Caris also provides molecular data and research services to biopharmaceutical companies to support drug development and the study of cancer.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Caris Life Sciences Right Now?

Before you consider Caris Life Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Caris Life Sciences wasn't on the list.

While Caris Life Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines